RASSF5: An MST activator and tumor suppressor in vivo but opposite in vitro

Donninger, 2016, Ras signaling through RASSF proteins, Semin Cell Dev Biol, 10.1016/j.semcdb.2016.06.007

Zanconato, 2016, YAP/TAZ at the roots of cancer, Cancer Cell, 29, 783, 10.1016/j.ccell.2016.05.005

Sun, 2016, Cellular organization and cytoskeletal regulation of the hippo signaling network, Trends Cell Biol, 10.1016/j.tcb.2016.05.003

Fallahi, 2016, The MST/hippo pathway and cell death: a non-canonical affair, Genes (Basel), 7, 10.3390/genes7060028

Kapoor, 2014, Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer, Cell, 158, 185, 10.1016/j.cell.2014.06.003

Shao, 2014, KRAS and YAP1 converge to regulate EMT and tumor survival, Cell, 158, 171, 10.1016/j.cell.2014.06.004

Lin, 2016, The Hippo effector YAP regulates the response of cancer cells to MAPK pathway inhibitors, Mol Cell Oncol, 3, e1021441, 10.1080/23723556.2015.1021441

Nussinov, 2016, Oncogenic KRAS signaling and YAP1/beta-catenin: similar cell cycle control in tumor initiation, Semin Cell Dev Biol, 10.1016/j.semcdb.2016.04.001

Nussinov, 2016, Independent and core pathways in oncogenic KRAS signaling, Expert Rev Proteomics, 10.1080/14789450.2016.1209417

Lu, 2016, Drugging Ras GTPase: a comprehensive mechanistic and signaling structural view, Chem Soc Rev

Lu, 2016, Ras conformational ensembles, allostery, and signaling, Chem Rev, 116, 6607, 10.1021/acs.chemrev.5b00542

Prior, 2012, A comprehensive survey of Ras mutations in cancer, Cancer Res, 72, 2457, 10.1158/0008-5472.CAN-11-2612

Sharif, 2015, Cell density regulates cancer metastasis via the Hippo pathway, Future Oncol, 11, 3253, 10.2217/fon.15.268

Nussinov, 2015, Principles of K-Ras effector organization and the role of oncogenic K-Ras in cancer initiation through G1 cell cycle deregulation, Expert Rev Proteomics, 12, 669, 10.1586/14789450.2015.1100079

Muratcioglu, 2015, GTP-dependent K-Ras dimerization, Structure, 23, 1325, 10.1016/j.str.2015.04.019

Smith, 2014, Integrated RAS signaling defined by parallel NMR detection of effectors and regulators, Nat Chem Biol, 10, 223, 10.1038/nchembio.1435

Chen, 2016, Ras dimer formation as a new signaling mechanism and potential cancer therapeutic target, Mini Rev Med Chem, 16, 391, 10.2174/1389557515666151001152212

Jambrina, 2016, Phosphorylation of RAF kinase dimers drives conformational changes that facilitate transactivation, Angew Chem Int Ed Engl, 55, 983, 10.1002/anie.201509272

Peng, 2015, Inhibition of RAF isoforms and active dimers by LY3009120 leads to anti-tumor activities in RAS or BRAF mutant cancers, Cancer Cell, 28, 384, 10.1016/j.ccell.2015.08.002

Sayyed-Ahmad, 2016, Computational equilibrium thermodynamic and kinetic analysis of K-Ras dimerization through an effector binding surface suggests limited functional role, J Phys Chem B, 10.1021/acs.jpcb.6b02403

Jang, 2016, Membrane-associated Ras dimers are isoform-specific: K-Ras dimers differ from H-Ras dimers, Biochem J, 473, 1719, 10.1042/BCJ20160031

Banerjee, 2016, The disordered hypervariable region and the folded catalytic domain of oncogenic K-Ras4B partner in phospholipid binding, Curr Opin Struct Biol, 36, 10, 10.1016/j.sbi.2015.11.010

Hwang, 2014, Structural basis of the heterodimerization of the MST and RASSF SARAH domains in the Hippo signalling pathway, Acta Crystallogr D Biol Crystallogr, 70, 1944, 10.1107/S139900471400947X

Makbul, 2013, Structural and thermodynamic characterization of Nore1-SARAH: a small, helical module important in signal transduction networks, Biochemistry, 52, 1045, 10.1021/bi3014642

Stieglitz, 2008, Novel type of Ras effector interaction established between tumour suppressor NORE1A and Ras switch II, EMBO J, 27, 1995, 10.1038/emboj.2008.125

Nan, 2015, Ras-GTP dimers activate the Mitogen-Activated Protein Kinase (MAPK) pathway, Proc Natl Acad Sci U S A, 112, 7996, 10.1073/pnas.1509123112

Kovrigina, 2015, The Ras G domain lacks the intrinsic propensity to form dimers, Biophys J, 109, 1000, 10.1016/j.bpj.2015.07.020

Zhou, 2015, Ras nanoclusters: versatile lipid-based signaling platforms, Biochim Biophys Acta, 1853, 841, 10.1016/j.bbamcr.2014.09.008

Zhou, 2014, Signal integration by lipid-mediated spatial cross talk between Ras nanoclusters, Mol Cell Biol, 34, 862, 10.1128/MCB.01227-13

Ni, 2013, Structural basis for autoactivation of human Mst2 kinase and its regulation by RASSF5, Structure, 21, 1757, 10.1016/j.str.2013.07.008

Avruch, 2012, Protein kinases of the Hippo pathway: regulation and substrates, Semin Cell Dev Biol, 23, 770, 10.1016/j.semcdb.2012.07.002

Creasy, 1996, The Ste20-like protein kinase, Mst1, dimerizes and contains an inhibitory domain, J Biol Chem, 271, 21049, 10.1074/jbc.271.35.21049

Hwang, 2007, Structural insight into dimeric interaction of the SARAH domains from Mst1 and RASSF family proteins in the apoptosis pathway, Proc Natl Acad Sci U S A, 104, 9236, 10.1073/pnas.0610716104

Richter, 2009, The RASSF proteins in cancer; from epigenetic silencing to functional characterization, Biochim Biophys Acta, 1796, 114

Avruch, 2009, Rassf family of tumor suppressor polypeptides, J Biol Chem, 284, 11001, 10.1074/jbc.R800073200

Aoyama, 2004, Nore1 inhibits tumor cell growth independent of Ras or the MST1/2 kinases, Oncogene, 23, 3426, 10.1038/sj.onc.1207486

Guo, 2007, RASSF1A is part of a complex similar to the Drosophila Hippo/Salvador/Lats tumor-suppressor network, Curr Biol, 17, 700, 10.1016/j.cub.2007.02.055

Oh, 2006, Role of the tumor suppressor RASSF1A in Mst1-mediated apoptosis, Cancer Res, 66, 2562, 10.1158/0008-5472.CAN-05-2951

Ikeda, 2009, Hippo pathway-dependent and -independent roles of RASSF6, Sci Signal, 2, ra59, 10.1126/scisignal.2000300

Khokhlatchev, 2002, Identification of a novel Ras-regulated proapoptotic pathway, Curr Biol, 12, 253, 10.1016/S0960-9822(02)00683-8

Praskova, 2004, Regulation of the MST1 kinase by autophosphorylation, by the growth inhibitory proteins, RASSF1 and NORE1, and by Ras, Biochem J, 381, 453, 10.1042/BJ20040025

Cooper, 2009, RASSF2 associates with and stabilizes the proapoptotic kinase MST2, Oncogene, 28, 2988, 10.1038/onc.2009.152

Song, 2010, Role of the tumor suppressor RASSF2 in regulation of MST1 kinase activity, Biochem Biophys Res Commun, 391, 969, 10.1016/j.bbrc.2009.11.175

Vos, 2003, The pro-apoptotic Ras effector Nore1 may serve as a Ras-regulated tumor suppressor in the lung, J Biol Chem, 278, 21938, 10.1074/jbc.M211019200

Calvisi, 2009, NORE1A tumor suppressor candidate modulates p21CIP1 via p53, Cancer Res, 69, 4629, 10.1158/0008-5472.CAN-08-3672

Park, 2010, Tumor suppressor ras association domain family 5 (RASSF5/NORE1) mediates death receptor ligand-induced apoptosis, J Biol Chem, 285, 35029, 10.1074/jbc.M110.165506

Calvisi, 2006, Ubiquitous activation of Ras and Jak/Stat pathways in human HCC, Gastroenterology, 130, 1117, 10.1053/j.gastro.2006.01.006

Calvisi, 2008, Ras-driven proliferation and apoptosis signaling during rat liver carcinogenesis is under genetic control, Int J Cancer, 123, 2057, 10.1002/ijc.23720

Sanchez-Sanz, 2016, MST2-RASSF protein-protein interactions through SARAH domains, Brief Bioinform, 17, 593, 10.1093/bib/bbv070

Chavan, 2015, Plasma membrane regulates Ras signaling networks, Cell Logist, 5, e1136374, 10.1080/21592799.2015.1136374

Cho, 2013, Ras nanoclusters: a new drug target?, Small GTPases, 4, 57, 10.4161/sgtp.23145

Kerkhoff, 1998, Cell cycle targets of Ras/Raf signalling, Oncogene, 17, 1457, 10.1038/sj.onc.1202185

Ewen, 2000, Relationship between Ras pathways and cell cycle control, Prog Cell Cycle Res, 4, 1, 10.1007/978-1-4615-4253-7_1

Zhang, 2002, MAPK signal pathways in the regulation of cell proliferation in mammalian cells, Cell Res, 12, 9, 10.1038/sj.cr.7290105

Donninger, 2014, Cell cycle restriction is more important than apoptosis induction for RASSF1A protein tumor suppression, J Biol Chem, 289, 31287, 10.1074/jbc.M114.609537

Zhang, 2012, Wnt/beta-catenin signaling pathway upregulates c-Myc expression to promote cell proliferation of P19 teratocarcinoma cells, Anat Rec (Hoboken), 295, 2104, 10.1002/ar.22592

Kaveri, 2013, beta-Catenin activation synergizes with Pten loss and Myc overexpression in Notch-independent T-ALL, Blood, 122, 694, 10.1182/blood-2012-12-471904

Juan, 2014, Diminished WNT->beta-catenin->c-MYC signaling is a barrier for malignant progression of BRAFV600E-induced lung tumors, Genes Dev, 28, 561, 10.1101/gad.233627.113

Palomero, 2006, NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth, Proc Natl Acad Sci U S A, 103, 18261, 10.1073/pnas.0606108103

Dongre, 2014, Non-canonical notch signaling drives activation and differentiation of peripheral CD4(+) T cells, Front Immunol, 5, 54, 10.3389/fimmu.2014.00054

Sharma, 2015, PI3K/AKT/mTOR and sonic hedgehog pathways cooperate together to inhibit human pancreatic cancer stem cell characteristics and tumor growth, Oncotarget, 6, 32039, 10.18632/oncotarget.5055

Ramaswamy, 2012, Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway, Cancer Res, 72, 5048, 10.1158/0008-5472.CAN-12-1248

Kern, 2015, Hedgehog/GLI and PI3K signaling in the initiation and maintenance of chronic lymphocytic leukemia, Oncogene, 34, 5341, 10.1038/onc.2014.450

Ilic, 2011, PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis, Proc Natl Acad Sci U S A, 108, E699, 10.1073/pnas.1108237108

Cope, 2014, Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation, J Cell Sci, 127, 788, 10.1242/jcs.137588

Boussemart, 2014, eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies, Nature, 513, 105, 10.1038/nature13572

Muellner, 2011, A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer, Nat Chem Biol, 7, 787, 10.1038/nchembio.695

Nussinov, 2013, A broad view of scaffolding suggests that scaffolding proteins can actively control regulation and signaling of multienzyme complexes through allostery, Biochim Biophys Acta, 1834, 820, 10.1016/j.bbapap.2012.12.014

Nussinov, 2013, ‘Pathway drug cocktail’: targeting Ras signaling based on structural pathways, Trends Mol Med, 19, 695, 10.1016/j.molmed.2013.07.009